Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure

Table 1 Demographics and clinical characteristics of study subjects

	Health control (n = 33)	CHB (n = 55)	ACLF (n = 81)	P value
Male	26 (78.79)	46 (83.64)	68 (83.95)	0.788
Age (yr)	39.73 ± 7.12	38.62 ± 12.08	42.84 ± 11.12	0.075
HBV DNA viral load (Log)	-	6.66 ± 1.49	5.76 ± 1.73	0.000
ALT (U/L)	18.71 ± 9.33	212.07 ± 290.77	527.06 ± 790.14	< 0.0001
AST (U/L)	21.70 ± 11.84	109.85 ± 158.32	401.72 ± 571.31	< 0.0001
Total bilirubin (μmol/L)	11.07 ± 3.47	28.43 ± 30.72	394.98 ± 200.16	< 0.0001
Albumin (g/L)	46.17 ± 2.05	40.02 ± 3.73	31.06 ± 3.99	< 0.0001
Crea (μmol/L)	66.72 ± 16.14	72.10 ± 12.66	80.96 ± 50.26	0.1768
International normalized ratio	-	1.03 ± 0.11	2.40 ± 1.00	< 0.0001
Prothrombin activity	-	98.86% ± 17.34%	31.34% ± 11.24%	< 0.0001
White blood cell (× 109/L)	5.85 ± 1.22	5.23 ± 1.30	8.19 ± 3.79	< 0.0001
Platelet (× 1012/L)	223.55 ± 22.09	170.72 ± 56.45	105.90 ± 58.13	< 0.0001

Data are presented as numbers (percentage) or mean ± SD. CHB: Chronic hepatitis B; ACLF: Acute-on-chronic liver failure; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.